Additional Approaches to Treatment in Pulmonary Tuberculosis

Neval METİN ÇAKARa , Ela ERDEM ERALPa

aMarmara University Faculty of Medicine, Department of Pediatric Chest Diseases, İstanbul, Türkiye

ABSTRACT
Tuberculosis is a disease caused by Mycobacterium tuberculosis bacterium (MTB), which is mostly affected by the lungs, transmitted by the respiratory tract, and is more common in underdeveloped and developing countries. Directly observed therapy (DOT) and antituberculosis agents are used in the treatment. In some cases, steroid usage and surgical treatment are included in addition to classical antituberculosis treatment. The fact that the treatment of the disease is long-term and the use of large amounts of pills in the treatment makes it difficult for the patients to comply with the treatment. For all these reasons, patients’ adherence to treatment decreases and the problem of multidrug-resistance (MDR) and extensively drug-resistance (XDR) comes to the fore. The growing problem of MDR and XDR has driven researchers to seek new approaches in the treatment of MTB.
Keywords: Tuberculosis; Mycobacterium tuberculosis; steroid; surgery

Referanslar

  1. Cunba BA. Pulmonary tuberculosis and steroids. Chest. 1995;107(6):1486-7. [Crossref]  [PubMed]
  2. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. [Crossref]  [PubMed]  [PMC]
  3. Paediatric TB Management Guideline. Ministry of health & family welfare government of India. 2022.
  4. Dooley DP, Carperter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 1997; 25:872-87. [Crossref]  [PubMed]
  5. Kathamuthu GR, Moideen K, Sridhar R, Baskaran D, Babu S. Enhanced Mycobacterial Antigen-Induced Pro-Inflammatory Cytokine Production in Lymph Node Tuberculosis. Am J Trop Med Hyg. 2019;100(6):1401-6. [Crossref]  [PubMed]  [PMC]
  6. Mellado Peña MJ, Santiago García B, Baquero-Artigao F, Moreno Pérez D, Piñeiro Pérez R, Méndez Echevarría A, et al. Tuberculosis treatment for children: An update. Spanish associatıon of paediatrics. 2018;88(1):52.e1-52.e12. [Crossref]
  7. Yang JY, Han M, Koh Y, Kim WS, Song JW, Oh YM, et al. Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients With Acute Respiratory Failure: A Propensity Analysis of Mortality. Clin Infect Dis. 2016;63(11): 1449-55. [Crossref]  [PubMed]
  8. Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev. 2014;2014(11): CD011370. [Crossref]  [PubMed]  [PMC]
  9. Varaine F, Rich ML. Tuberculosis. MSF Medical Guidelines. 2014.
  10. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India. 2009;26(1):9-16. [Crossref]  [PubMed]  [PMC]
  11. Çakır E, Erdem Eralp E. Çocuklarda tüberküloz ve tüberküloz cerrahisi. Çocuk Göğüs Cerrahisi. İstanbul: Akademisyen Kitabevi; 2018. p.401-9.
  12. Subotic D, Yablonskiy P, Sulis G, Cordos I, Petrov D, Centis R, et al. Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. J Thorac Dis. 2016;8(7):E474-85. [Crossref]  [PubMed]  [PMC]
  13. Kır A, İskender I. Tüberküloz cerrahisi. Ch. 39. Özkara S, Kılıçaslan Z, editörler. Tüberküloz. Türk Toraks Derneği. 2015. p. 554-64.